Encompass Health Corporation Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
Encompass Health Corporation (EHC) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of $154.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-08-07
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-06-30 was $154.50M, a 8.04% increase year-over-year.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-03-31 was $178.60M, a 17.50% increase year-over-year.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-12-31 was $145.30M, a 20.58% increase year-over-year.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-09-30 was $126.90M, a 16.53% increase year-over-year.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2025 was $567.20M, a 23.71% increase from fiscal 2024.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2024 was $458.50M, a 25.96% increase from fiscal 2023.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was $364.00M, a 41.58% increase from fiscal 2022.
- Encompass Health Corporation net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was $257.10M, a 14.27% decline from fiscal 2021.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $154.50M 10-Q · filed 2026-08-07 | $333.10M 10-Q · filed 2026-08-07 | $478.40M derived: sum of 3 quarters · filed 2026-08-07 | $605.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $178.60M 10-Q · filed 2026-05-01 | $323.90M derived: sum of 2 quarters · filed 2026-05-01 | $450.80M derived: sum of 3 quarters · filed 2026-05-01 | $593.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $145.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $272.20M derived: sum of 2 quarters · filed 2026-02-26 | $415.20M derived: sum of 3 quarters · filed 2026-08-07 | $567.20M 10-K · filed 2026-02-26 |
| 2025-09-30 | $126.90M 10-Q · filed 2025-10-31 | $269.90M derived: sum of 2 quarters · filed 2026-08-07 | $421.90M 10-Q · filed 2025-10-31 | $542.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $143.00M 10-Q · filed 2026-08-07 | $295.00M 10-Q · filed 2026-08-07 | $415.50M derived: sum of 3 quarters · filed 2026-08-07 | $524.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $152.00M 10-Q · filed 2026-05-01 | $272.50M derived: sum of 2 quarters · filed 2026-05-01 | $381.40M derived: sum of 3 quarters · filed 2026-05-01 | $496.70M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $120.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $229.40M derived: sum of 2 quarters · filed 2026-02-26 | $344.70M derived: sum of 3 quarters · filed 2026-02-26 | $458.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $108.90M 10-Q · filed 2025-10-31 | $224.20M derived: sum of 2 quarters · filed 2025-10-31 | $338.00M 10-Q · filed 2025-10-31 | $434.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $115.30M 10-Q · filed 2025-08-06 | $229.10M 10-Q · filed 2025-08-06 | $325.20M derived: sum of 3 quarters · filed 2026-02-26 | $411.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $113.80M 10-Q · filed 2025-05-01 | $209.90M derived: sum of 2 quarters · filed 2026-02-26 | $296.50M derived: sum of 3 quarters · filed 2026-02-26 | $389.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $96.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $182.70M derived: sum of 2 quarters · filed 2026-02-26 | $275.30M derived: sum of 3 quarters · filed 2026-02-26 | $364.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $86.60M 10-Q · filed 2024-11-01 | $179.20M derived: sum of 2 quarters · filed 2024-11-01 | $267.90M 10-Q · filed 2024-11-01 | $358.80M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $92.60M 10-Q · filed 2024-08-06 | $181.30M 10-Q · filed 2024-08-06 | $272.20M derived: sum of 3 quarters · filed 2025-02-28 | $336.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $88.70M 10-Q · filed 2024-05-02 | $179.60M derived: sum of 2 quarters · filed 2025-02-28 | $243.50M derived: sum of 3 quarters · filed 2025-02-28 | $281.40M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $90.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $154.80M derived: sum of 2 quarters · filed 2025-02-28 | $192.70M derived: sum of 3 quarters · filed 2025-02-28 | $257.10M 10-K · filed 2025-02-28 |
| 2022-09-30 | $63.90M 10-Q · filed 2023-11-01 | $101.80M derived: sum of 2 quarters · filed 2023-11-01 | $166.20M 10-Q · filed 2023-11-01 | $234.80M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $37.90M 10-Q · filed 2023-08-04 | $102.30M 10-Q · filed 2023-08-04 | $170.90M derived: sum of 3 quarters · filed 2024-02-28 | $246.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $64.40M 10-Q · filed 2023-05-03 | $133.00M derived: sum of 2 quarters · filed 2024-02-28 | $208.80M derived: sum of 3 quarters · filed 2024-02-28 | |
| 2021-12-31 | $68.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $144.40M derived: sum of 2 quarters · filed 2024-02-28 | $299.90M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $75.80M 10-Q · filed 2022-11-02 | $231.30M 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | $194.90M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pediatrix Medical Group, Inc. (MD) | United States | $2.084B | 11.76 |